Compile Data Set for Download or QSAR
Report error Found 388 Enz. Inhib. hit(s) with all data for entry = 1416
TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321726(US10183021, Compound I-522)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321718(US10183021, Compound I-518)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321721(US10183021, Compound I-478)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321724(US10183021, Compound I-521)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321486(US10183021, Compound I-214)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321485(US10183021, Compound I-16)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321488(US10183021, Compound I-219)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321744(US10183021, Compound I-531)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321487(US10183021, Compound I-19)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321743(US10183021, Compound I-487)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321490(US10183021, Compound I-221)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321489(US10183021, Compound I-24)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321492(US10183021, Compound I-230)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321748(US10183021, Compound I-420)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321482(US10183021, Compound I-206)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321484(US10183021, Compound I-213)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321739(US10183021, Compound I-485)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321758(US10183021, Compound I-537)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321504(US10183021, Compound I-250)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321760(US10183021, Compound I-538)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321588(US10183021, Compound I-407 | US10183021, Compound ...)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321506(US10183021, Compound I-306)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321494(US10183021, Compound I-236)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321496(US10183021, Compound I-239)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321495(US10183021, Compound I-41)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321500(US10183021, Compound I-187)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321756(US10183021, Compound I-536)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321499(US10183021, Compound I-54)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321772(US10183021, Compound I-545)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321520(US10183021, Compound I-364)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321524(US10183021, Compound I-366)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321510(US10183021, Compound I-361)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321765(US10183021, Compound I-496)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321516(US10183021, Compound I-454)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321771(US10183021, Compound I-544)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321515(US10183021, Compound I-89)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321534(US10183021, Compound I-370)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321533(US10183021, Compound I-126)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321536(US10183021, Compound I-268)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321538(US10183021, Compound I-371)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321793(US10183021, Compound I-608)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321537(US10183021, Compound I-129)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321526(US10183021, Compound I-455)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321528(US10183021, Compound I-367)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321529(US10183021, Compound I-111 | US10183021, Compound ...)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321532(US10183021, Compound I-369)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321550(US10183021, Compound I-374)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321551(US10183021, Compound I-162)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321556(US10183021, Compound I-305)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321555(US10183021, Compound I-452)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

Displayed 1 to 50 (of 388 total ) | Next | Last >>
Jump to: